` Comparison: 2397 vs TMO - Alpha Spread

D
2397
vs
TMO

Over the past 12 months, DNA Chip Research Inc has significantly outperformed TMO, delivering a return of +91 308% compared to the TMO's 3% drop.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
2397
TMO
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

D
Intrinsic Value
232 969.3906 JPY
Overvaluation 77%
Intrinsic Value
Price
TMO Intrinsic Value
490.53 USD
Overvaluation 5%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
D
DNA Chip Research Inc
TSE:2397
999 999.9999 JPY
Thermo Fisher Scientific Inc
NYSE:TMO
515.48 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
2397, TMO

2397
TMO
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
D
DNA Chip Research Inc
Revenue
Thermo Fisher Scientific Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
2397, TMO

2397
TMO
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
D
DNA Chip Research Inc
TSE:2397
Thermo Fisher Scientific Inc
NYSE:TMO
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

DNA Chip Research Inc
52.3%
TMO
41.5%

Operating Margin

DNA Chip Research Inc
3.6%
TMO
18.2%

Net Margin

DNA Chip Research Inc
-5.3%
TMO
15%

FCF Margin

DNA Chip Research Inc
2.4%
TMO
14.1%

ROE

DNA Chip Research Inc
-8.3%
TMO
13%

ROA

DNA Chip Research Inc
-5.9%
TMO
6.5%

ROIC

DNA Chip Research Inc
8%
TMO
7.9%

ROCE

DNA Chip Research Inc
5.3%
TMO
9.1%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
2397, TMO

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2397, TMO

Loading
2397
TMO
Difference
www.alphaspread.com

Performance By Year
2397, TMO

Loading
2397
TMO
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 2397 to other stocks
0KHE
PerkinElmer Inc
P
More expensive
vs DNA Chip Research Inc
DHR
Danaher Corp
Cheaper
vs DNA Chip Research Inc
207940
Samsung Biologics Co Ltd
Cheaper
vs DNA Chip Research Inc
LONN
Lonza Group AG
Cheaper
vs DNA Chip Research Inc
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett